John F Tisdale MD
Hematology/Oncology
Senior Investigator/National Institutes of Health
Join to View Full Profile
8600 Old Georgetown RdBethesda, MD 20814
Phone+1 301-896-3517
Fax+1 301-493-4259
Dr. Tisdale is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
Vanderbilt University Medical CenterResidency, Internal Medicine, 1990 - 1994
Medical University of South CarolinaClass of 1990
Certifications & Licensure
MD State Medical License 2004 - 2027
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease Start of enrollment: 2001 Nov 01
- Stem Cell Collection for Adult Volunteers Start of enrollment: 2002 Apr 29
- Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia Start of enrollment: 2003 Mar 10
Publications & Presentations
PubMed
- Fetal Hemoglobin Research and Clinical Relevance in Sickle Cell Disease.Bjorg Gudmundsdottir, John F Tisdale
Physiology. 2026-09-01 - Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.Kyle C Kern, Zaina Inam, Matthew M Hsieh, John F Tisdale, Courtney D Fitzhugh
Neurology. 2026-06-09 - Clonal dynamics, tolerance, and adverse events after CD45-ADC-conditioned autologous HSPC transplantation in macaques.Taha Bartu Hayal, Diana M Abraham, Selami Demirci, Xing Fan, Yifan Zhou
Blood Advances. 2026-04-14
Journal Articles
- Transfusion Support for Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation (1993–2010): Factors That Predict Intensity and Time to Transfusion Independ...Richard W Childs, John F Tisdale, Transfusion
Abstracts/Posters
- The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene TherapyJohn F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene TherapyJohn F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using PlerixaforJohn F. Tisdale, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease60th American Society of Hematology Annual Meeting - 12/2/2018
- Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease60th American Society of Hematology Annual Meeting - 12/1/2018
- Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaJanuary 3rd, 2023- Health News | Experimental Gene Therapy Reverses Sickle Cell Disease for Years: StudyJanuary 1st, 2022
- Study Finds Experimental Gene Therapy Reverses Sickle Cell Disease for YearsDecember 27th, 2021
Grant Support
- 14C As A Marker For Beta Cell Turnover In Adult HumansNational Center For Research Resources2011
- Nonmyeloablative Allogeneic PBSC In Globin DisordersNational Heart, Lung, And Blood Institute2009–2011
- Isolation, Characterization, And Transplantation Of Candidate Stem CellsNational Heart, Lung, And Blood Institute2009–2011
- A Preclinical Large Animal Model For Globin Gene TransferNational Heart, Lung, And Blood Institute2009–2011
- Development Of Improved Lentiviral Vectors For Human Gene Therapy ApplicationsNational Heart, Lung, And Blood Institute2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
